These observations elucidate the role of the SMYD3/H3K4me3/PKM2 axis in DLBCL and indicate that SMYD3 may be a novel prognostic biomarker and/or therapeutic target for DLBCL. The gene discussed is PKM; the disease is diffuse large B-cell lymphoma.